Akeso is committed to developing first-in-class and best-in-class new drugs through efficient and groundbreaking R&D innovation. Since its establishment, the Company has been committed to building fully integrated internal development capabilities. An end-to-end drug development platform, the Akeso Comprehensive Exploration Platform (ACE Platform), has been developed with great foresight, encompassing functionalities including drug target validation, antibody discovery and preclinical study, CMC manufacturing process development and GMP-compliant commercialization production.
The ACE platform runs through the full life cycle of drug candidates through development to production and commercialization, and reducing our reliance on the external service system. In addition,it ensures and promote the efficient operation of the new drug development process, thereby increasing the possibility of success rate and reducing the development cost. Based on this platform, we have developed over 50 innovative drug candidates with fully independent intellectual property rights, focusing on major diseases such as tumors and autoimmune, inflammatory and metabolic diseases. Among them, 26 drug candidates have entered clinical strage, with their production processes being developed by the internal platform.
Tetrabody technology is a proprietary technology independently developed by Akeso for the design and manufacture of innovative tetravalent bispecific antibodies. It overcomes CMC challenges such as low expression levels due to the high molecular weight of bispecific antibodies, process development obstacles due to the structural heterogeneity of bispecific antibodies, and non-druggability due to the lack of stability of bispecific antibodies.
Using our unique Tetrabody technology, we have successfully developed 15+ innovative, world-leading bispecific antibody,multi-specific antibody and BsAb ADC drugs, including开坦尼® (PD-1/CTLA-4 bispecific antibody, Cadonilimab injection),依达方® (PD-1/VEGF bi-specific antibody,Ivonescimab injection) and AK130,etc. 开坦尼® is the world's first commercialized dual immune checkpoint inhibitor bispecific antibody to treat cancer. 依达方® is the world's first PD-1/VEGF bispecific antibody drug; and AK130 is the world's first and only TIGIT/TGF-β dual-targeting antibody fusion protein in research. This results fully demonstrate the strength of Akeso's innovative development strength and its leading position in the field of bispecific antibodies.
Akeso is vigorously promoting research on bispecific antibody-based combination therapies ，ushering in a new era of tumor immunotherapy (IO 2.0). Based on Cadonilimab and Ivonescimab, the exploration of combination therapies with many self-developed products or other drugs has shown promising synergies recently, and is expected to provide patients with superior therapeutic benefit. The social and industrial value of Akeso's innovative drugs will be fully presented in this development strategy.
Akeso strategically focuses on three core and cutting-edge areas in biopharmaceuticals—antibody proteins, siRNA、mRNA, and cell therapy—mastering core technologies across the entire development chain with fully independent intellectual property rights.
ADC Technology Platform：Leveraging its leading edge in multi-specific antibodies, Akeso independently developed a unique Antibody-Drug Conjugate (ADC) technology platform, resulting in the development of several pioneering third-generation ADCs and bispecific ADC products.
mRNA Technology Platform： Akeso is pioneering the biopharmaceutical field by developing a comprehensive technology platform that spans from mRNA sequence design to delivery systems, currently advancing mRNA therapeutic cancer vaccines and gene therapy product pipelines, with a global first-mover advantage.
Cell Therapy Technology Platform ：Keeping pace with the forefront of biotechnology, Akeso is pioneering a novel CARL-NK cell therapy drug development platform, enhancing NK cell genetic engineering optimization across multiple dimensions using its existing innovative technologies.
